A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement

This Phase II study is testing a combination of two drugs — pemigatinib (a targeted therapy) and durvalumab (an immunotherapy) — in people with a bile duct cancer called intrahepatic cholangiocarcinoma that has a specific genetic change (FGFR2 fusion or rearrangement). The trial is for patients whose cancer has progressed after prior treatment. **You may be eligible if...** - You are 18 or older - You have been diagnosed with locally advanced or metastatic intrahepatic cholangiocarcinoma (bile duct cancer) - Your tumor has a confirmed FGFR2 fusion or rearrangement (via an approved genetic test) - You have received prior treatment including gemcitabine, cisplatin, and an anti-PD-1 drug, and your cancer has progressed or you could not tolerate chemotherapy - You have at least one measurable tumor on scans - Your organ function meets required thresholds - You are willing to use effective contraception **You may NOT be eligible if...** - You have had prior treatment with an FGFR inhibitor drug - You have significant eye problems (corneal or retinal disorders) - You have active autoimmune disease (like lupus, Crohn's, or rheumatoid arthritis) - You have active hepatitis B, C, or HIV - You have active brain metastases or history of organ transplant - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.